>Onyx Pharmaceuticals: Lung Data Coming out Mid-Year

April 21, 2010

>Our New York presenter continues to recommend Onyx (NASDAQ: ONXX, $29.14). The company has said that the data from a Phase III trial in lung cancer for its main product Nexavar would come out mid-year. Nexavar has been approved for breast cancer and is being tested in other indications. If the lung data is positive, the stock will go up dramatically, but the downside should the results dissapoint is limited to 5-10%, in the presenter’s opinion. He would add to his postion aggressively if the date is negative. The Street is underestimating Nexavar’s potential in breast cancer and is not giving enough credit to the drug’s prospects in other types of cancer.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: